Zenas BioPharma Shares Jump 30.8% on Encouraging Phase II Obexelimab Data
Zenas BioPharma’s share price surged 30.78% over the past month and 241.61% over 52 weeks, closing at $26.68 with a $1.432 billion market cap as of February 18, 2026. Meridian Small Cap Growth Fund flagged encouraging Phase II data on lead candidate Obexelimab in Q4 and projects potential annual revenues exceeding $1 billion pending approvals.
1. Stock Performance
Zenas BioPharma shares climbed 30.78% in the past month and 241.61% over the last 52 weeks, closing at $26.68 on February 18, 2026, with a market capitalization of $1.432 billion. This rapid appreciation reflects growing investor optimism around its clinical pipeline and revenue potential.
2. Phase II Trial Data
In Q4, investors noted strong Phase II trial results for Obexelimab, the company’s lead autoimmune therapy, indicating favorable safety and efficacy signals. These data helped drive the stock’s recent rally by reinforcing confidence in the drug’s development trajectory.
3. Obexelimab Development & Revenue Outlook
Obexelimab is in Phase III trials with a targeted approval and launch window in 2027. Multiple indications are under investigation, and successful development could support annual revenues exceeding $1 billion, contingent on regulatory green lights.
4. Hedge Fund Interest
At the end of Q3 2025, 13 hedge fund portfolios held Zenas BioPharma shares, the same number as the prior quarter, signaling steady institutional interest despite broader sector volatility.